摘要
In a recent study published in Cell,Wang X et al.1 reported the first use of allogeneic anti-CD19 CAR T cells in patients with therapyresistant autoimmune diseases,demonstrating their effectiveness in reducing disease activity,with good tolerability and persistence.These findings suggest that allogeneic CAR T cells could offer a scalable,off-the-shelf treatment option for autoimmune disorders.
基金
supported by the Deutsche Forschungsgemeinschaft(DFG,project nr.536993790)
the European Regional Development Fund(project ZELL-THEMA).
作者简介
Correspondence:Dimitrios Mougiakakos,dimitrios.mougiakakos@med.ovgu.de。
